Susquehanna Portfolio Strategies, LLC C4 Therapeutics, Inc. Transaction History
Susquehanna Portfolio Strategies, LLC
- $4.58 Trillion
- Q2 2025
A detailed history of Susquehanna Portfolio Strategies, LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna Portfolio Strategies, LLC holds 126,900 shares of CCCC stock, worth $302,022. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,900Holding current value
$302,022% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CCCC
# of Institutions
102Shares Held
59.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$17.7 Million0.06% of portfolio
-
Lynx1 Capital Management LP San Juan, PR7.1MShares$16.9 Million3.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$16.6 Million0.77% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$16.3 Million0.35% of portfolio
-
Morgan Stanley New York, NY4.75MShares$11.3 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $116M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...